DELCATH SYSTEMS, INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Surgical & Medical Instruments & Apparatus.
The next scheduled catalyst is Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease on December 15, 2026. There are 3 upcoming events on record.
DELCATH SYSTEMS, INC. generates cash from operations, so a burn-based runway figure does not apply.
Across 5 concluded trials, 60% reached completion rather than being terminated or withdrawn.
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.